… Thus, iPSC-derived cancer organoid technology is expected to expand during the next
decade, with several models developed for other cancers (39, 40) with increasing implication of …

… Thus, combining these cells and 3D models or obtaining organoids from iPSCs can provide
an improved model for predicting disease and tailoring personalized therapy for patients. In …

… Moreover, regenerative medicine has highlighted the ability of … a possible application in
personalized therapy 73 . … still need to be made to improve the organoid model system. First, …

… of organoid applications in regenerative medicine has opened a new window for a better …
Tumoroids are preclinical models to elaborate on personalized drugs and screen them before …

… Patient-derived tumour organoids (PDOs) have revolutionised our understanding of cancer
biology and the applications of personalised therapies. These advancements are principally …

… organoid technology as a promising, expanding strategy to study cancer and to develop
personalized therapeutic … the selection of therapeutic treatments and to improve management of …

… of individualized treatment and improve patient prognosis. However, genotype-based cancer
precision medicine … in tissue engineering, regenerative medicine, disease modeling, drug …

… toward organoid-guided personalized cancer immunotherapy. … model that allows better
translation from bench to bedside. Tumor-derived organoids have shown promise for modeling …

… can be exploited to enhance β-cell generation from organoids (Figure 1). … derived organoids
(PDOs) with the aim to use them as avatar models to define more personalized therapies. …

… organoid technology may allow the future development of individualized therapies for lung
cancer … advent of patient-derived organoids (PDOs) provided a further improvement to tumor …